0R1F.L
Bristol-Myers Squibb Company
0R1F.L
(0.0)72,70 USD
-13.81% ROA
-23.01% ROE
-23.91x PER
118.660.935.347,00 USD
347.12% DER
1.65% Yield
-13.5% NPM
Bristol-Myers Squibb Company Stock Analysis
Bristol-Myers Squibb Company Fundamental Analysis
Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.
| # | Analysis | Rating |
|---|---|---|
| 1 |
ROE
Unidentified ROE |
|
| 2 |
ROA
Unidentified ROA |
|
| 3 |
PBV
Unidentified ROA |
|
| 4 |
DER
Unidentified DER |
|
| 5 |
Revenue Growth
Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice. |
|
| 6 |
Net Profit Growth
This company's net profit has remained stagnant over the past five years, indicating a lack of growth and making it a less favorable investment option. |
|
| 7 |
Assets Growth
Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice. |
|
| 8 |
Graham Number
Unidentified Graham Number |
|
| 9 |
Dividend Growth
The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity. |
|
| 10 |
Dividend
The company has not distributed any dividends in the past three years, which may raise concerns for investors looking for regular income from their investments. |
|
| 11 |
Buffet Intrinsic Value
Based on Warren Buffett's formula, the company's stock seems overpriced (0), indicating a potential drawback for investors as its market price exceeds its estimated intrinsic value. |
Bristol-Myers Squibb Company Technical Analysis
Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.
| # | Analysis | Recommendation |
|---|---|---|
| 1 | Awesome Oscillator | Sell |
| 2 | MACD | Sell |
| 3 | RSI | Hold |
| 4 | Stoch RSI | Hold |
Bristol-Myers Squibb Company Price Chart
Financial Statements
Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.
Income Statements
An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.
Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.
| Year | Revenue | Growth |
|---|---|---|
| 2012 | 17.621.000.000 | |
| 2013 | 16.385.000.000 | -7.54% |
| 2014 | 15.879.000.000 | -3.19% |
| 2015 | 16.560.000.000 | 4.11% |
| 2016 | 19.427.000.000 | 14.76% |
| 2017 | 20.776.000.000 | 6.49% |
| 2018 | 22.561.000.000 | 7.91% |
| 2019 | 26.145.000.000 | 13.71% |
| 2020 | 42.518.000.000 | 38.51% |
| 2021 | 46.385.000.000 | 8.34% |
| 2022 | 46.159.000.000 | -0.49% |
| 2023 | 43.864.000.000 | -5.23% |
| 2023 | 45.006.000.000 | 2.54% |
| 2024 | 47.460.000.000 | 5.17% |
Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.
| Year | Research and Development Expenses | Growth |
|---|---|---|
| 2012 | 3.904.000.000 | |
| 2013 | 3.731.000.000 | -4.64% |
| 2014 | 4.534.000.000 | 17.71% |
| 2015 | 5.920.000.000 | 23.41% |
| 2016 | 5.012.000.000 | -18.12% |
| 2017 | 6.468.000.000 | 22.51% |
| 2018 | 6.332.000.000 | -2.15% |
| 2019 | 6.148.000.000 | -2.99% |
| 2020 | 22.581.000.000 | 72.77% |
| 2021 | 11.354.000.000 | -98.88% |
| 2022 | 10.324.000.000 | -9.98% |
| 2023 | 9.288.000.000 | -11.15% |
| 2023 | 10.212.000.000 | 9.05% |
| 2024 | 62.576.000.000 | 83.68% |
General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.
| Year | General and Administrative Expenses | Growth |
|---|---|---|
| 2012 | 4.135.000.000 | |
| 2013 | 4.068.000.000 | -1.65% |
| 2014 | 3.983.000.000 | -2.13% |
| 2015 | 4.006.000.000 | 0.57% |
| 2016 | 4.026.000.000 | 0.5% |
| 2017 | 4.009.000.000 | -0.42% |
| 2018 | 3.851.000.000 | -4.1% |
| 2019 | 4.336.000.000 | 11.19% |
| 2020 | 6.628.000.000 | 34.58% |
| 2021 | 6.352.000.000 | -4.35% |
| 2022 | 6.403.000.000 | 0.8% |
| 2023 | 0 | 0% |
| 2023 | 6.278.000.000 | 100% |
| 2024 | 0 | 0% |
EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.
| Year | EBITDA | Growth |
|---|---|---|
| 2012 | 5.289.000.000 | |
| 2013 | 4.180.000.000 | -26.53% |
| 2014 | 4.146.000.000 | -0.82% |
| 2015 | 4.435.000.000 | 6.52% |
| 2016 | 5.709.000.000 | 22.32% |
| 2017 | 4.563.000.000 | -25.12% |
| 2018 | 5.868.000.000 | 22.24% |
| 2019 | 7.798.000.000 | 24.75% |
| 2020 | 13.824.000.000 | 43.59% |
| 2021 | 19.329.000.000 | 28.48% |
| 2022 | 20.161.000.000 | 4.13% |
| 2023 | 18.220.000.000 | -10.65% |
| 2023 | 18.420.000.000 | 1.09% |
| 2024 | 19.016.000.000 | 3.13% |
Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.
| Year | Gross Profit | Growth |
|---|---|---|
| 2012 | 13.067.000.000 | |
| 2013 | 11.543.000.000 | -13.2% |
| 2014 | 12.098.000.000 | 4.59% |
| 2015 | 12.735.000.000 | 5% |
| 2016 | 14.479.000.000 | 12.05% |
| 2017 | 14.911.000.000 | 2.9% |
| 2018 | 16.151.000.000 | 7.68% |
| 2019 | 18.247.000.000 | 11.49% |
| 2020 | 30.745.000.000 | 40.65% |
| 2021 | 36.445.000.000 | 15.64% |
| 2022 | 36.378.000.000 | -0.18% |
| 2023 | 33.904.000.000 | -7.3% |
| 2023 | 34.488.000.000 | 1.69% |
| 2024 | 35.820.000.000 | 3.72% |
Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.
| Year | Net Profit | Growth |
|---|---|---|
| 2012 | 1.959.000.000 | |
| 2013 | 2.563.000.000 | 23.57% |
| 2014 | 2.004.000.000 | -27.89% |
| 2015 | 1.565.000.000 | -28.05% |
| 2016 | 4.457.000.000 | 64.89% |
| 2017 | 1.007.000.000 | -342.6% |
| 2018 | 4.920.000.000 | 79.53% |
| 2019 | 3.439.000.000 | -43.06% |
| 2020 | -9.015.000.000 | 138.15% |
| 2021 | 6.994.000.000 | 228.9% |
| 2022 | 6.327.000.000 | -10.54% |
| 2023 | 7.712.000.000 | 17.96% |
| 2023 | 8.025.000.000 | 3.9% |
| 2024 | -47.644.000.000 | 116.84% |
EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.
| Year | Earning per Share (EPS) | Growth |
|---|---|---|
| 2012 | 1 | |
| 2013 | 2 | 0% |
| 2014 | 1 | 0% |
| 2015 | 1 | 0% |
| 2016 | 3 | 100% |
| 2017 | 1 | 0% |
| 2018 | 3 | 100% |
| 2019 | 2 | -50% |
| 2020 | -4 | 166.67% |
| 2021 | 3 | 200% |
| 2022 | 3 | -50% |
| 2023 | 4 | 33.33% |
| 2023 | 4 | 0% |
| 2024 | -24 | 113.04% |
Cashflow Statements
Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.
Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.
| Year | Free Cashflow | Growth |
|---|---|---|
| 2012 | 6.393.000.000 | |
| 2013 | 3.008.000.000 | -112.53% |
| 2014 | 2.622.000.000 | -14.72% |
| 2015 | 1.285.000.000 | -104.05% |
| 2016 | 1.843.000.000 | 30.28% |
| 2017 | 4.220.000.000 | 56.33% |
| 2018 | 6.115.000.000 | 30.99% |
| 2019 | 7.374.000.000 | 17.07% |
| 2020 | 13.299.000.000 | 44.55% |
| 2021 | 15.234.000.000 | 12.7% |
| 2022 | 11.948.000.000 | -27.5% |
| 2023 | 4.409.000.000 | -170.99% |
| 2023 | 12.651.000.000 | 65.15% |
| 2024 | 2.550.000.000 | -396.12% |
Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.
| Year | Operating Cashflow | Growth |
|---|---|---|
| 2012 | 6.941.000.000 | |
| 2013 | 3.545.000.000 | -95.8% |
| 2014 | 3.148.000.000 | -12.61% |
| 2015 | 2.105.000.000 | -49.55% |
| 2016 | 3.058.000.000 | 31.16% |
| 2017 | 5.275.000.000 | 42.03% |
| 2018 | 7.066.000.000 | 25.35% |
| 2019 | 8.210.000.000 | 13.93% |
| 2020 | 14.052.000.000 | 41.57% |
| 2021 | 16.207.000.000 | 13.3% |
| 2022 | 13.066.000.000 | -24.04% |
| 2023 | 4.751.000.000 | -175.02% |
| 2023 | 13.860.000.000 | 65.72% |
| 2024 | 2.834.000.000 | -389.06% |
Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.
| Year | Capital Expenditure | Growth |
|---|---|---|
| 2012 | 548.000.000 | |
| 2013 | 537.000.000 | -2.05% |
| 2014 | 526.000.000 | -2.09% |
| 2015 | 820.000.000 | 35.85% |
| 2016 | 1.215.000.000 | 32.51% |
| 2017 | 1.055.000.000 | -15.17% |
| 2018 | 951.000.000 | -10.94% |
| 2019 | 836.000.000 | -13.76% |
| 2020 | 753.000.000 | -11.02% |
| 2021 | 973.000.000 | 22.61% |
| 2022 | 1.118.000.000 | 12.97% |
| 2023 | 342.000.000 | -226.9% |
| 2023 | 1.209.000.000 | 71.71% |
| 2024 | 284.000.000 | -325.7% |
Balance Sheet
Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.
Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.
| Year | Equity | Growth |
|---|---|---|
| 2012 | 13.638.000.000 | |
| 2013 | 15.236.000.000 | 10.49% |
| 2014 | 14.983.000.000 | -1.69% |
| 2015 | 14.424.000.000 | -3.88% |
| 2016 | 16.347.000.000 | 11.76% |
| 2017 | 11.847.000.000 | -37.98% |
| 2018 | 14.127.000.000 | 16.14% |
| 2019 | 51.698.000.000 | 72.67% |
| 2020 | 37.882.000.000 | -36.47% |
| 2021 | 36.006.000.000 | -5.21% |
| 2022 | 31.118.000.000 | -15.71% |
| 2023 | 29.485.000.000 | -5.54% |
| 2023 | 29.062.000.000 | -1.46% |
| 2024 | 16.548.000.000 | -75.62% |
Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.
| Year | Assets | Growth |
|---|---|---|
| 2012 | 35.897.000.000 | |
| 2013 | 38.592.000.000 | 6.98% |
| 2014 | 33.749.000.000 | -14.35% |
| 2015 | 31.748.000.000 | -6.3% |
| 2016 | 33.707.000.000 | 5.81% |
| 2017 | 33.551.000.000 | -0.46% |
| 2018 | 34.986.000.000 | 4.1% |
| 2019 | 129.944.000.000 | 73.08% |
| 2020 | 118.481.000.000 | -9.67% |
| 2021 | 109.314.000.000 | -8.39% |
| 2022 | 96.820.000.000 | -12.9% |
| 2023 | 95.159.000.000 | -1.75% |
| 2023 | 91.263.000.000 | -4.27% |
| 2024 | 99.031.000.000 | 7.84% |
Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.
| Year | Liabilities | Growth |
|---|---|---|
| 2012 | 22.259.000.000 | |
| 2013 | 23.356.000.000 | 4.7% |
| 2014 | 18.766.000.000 | -24.46% |
| 2015 | 17.324.000.000 | -8.32% |
| 2016 | 17.360.000.000 | 0.21% |
| 2017 | 21.704.000.000 | 20.01% |
| 2018 | 20.859.000.000 | -4.05% |
| 2019 | 78.246.000.000 | 73.34% |
| 2020 | 80.599.000.000 | 2.92% |
| 2021 | 73.308.000.000 | -9.95% |
| 2022 | 65.702.000.000 | -11.58% |
| 2023 | 65.674.000.000 | -0.04% |
| 2023 | 62.201.000.000 | -5.58% |
| 2024 | 82.483.000.000 | 24.59% |
Bristol-Myers Squibb Company Financial Ratio (TTM)
Valuation Metrics
- Revenue per Share
- 22.52
- Net Income per Share
- -3.04
- Price to Earning Ratio
- -23.91x
- Price To Sales Ratio
- 2.61x
- POCF Ratio
- 10.71
- PFCF Ratio
- 9.49
- Price to Book Ratio
- 8.92
- EV to Sales
- 3.66
- EV Over EBITDA
- 9.19
- EV to Operating CashFlow
- 12.14
- EV to FreeCashFlow
- 13.32
- Earnings Yield
- -0.04
- FreeCashFlow Yield
- 0.11
- Market Cap
- 118,66 Bil.
- Enterprise Value
- 166,57 Bil.
- Graham Number
- 23.62
- Graham NetNet
- -31.24
Income Statement Metrics
- Net Income per Share
- -3.04
- Income Quality
- -2.23
- ROE
- -0.23
- Return On Assets
- -0.06
- Return On Capital Employed
- 0.11
- Net Income per EBT
- 1.05
- EBT Per Ebit
- -0.7
- Ebit per Revenue
- 0.18
- Effective Tax Rate
- -0.15
Margins
- Sales, General, & Administrative to Revenue
- 0.01
- Research & Developement to Revenue
- 0.52
- Stock Based Compensation to Revenue
- 0.03
- Gross Profit Margin
- 0.76
- Operating Profit Margin
- 0.18
- Pretax Profit Margin
- -0.13
- Net Profit Margin
- -0.14
Dividends
- Dividend Yield
- 0.02
- Dividend Yield %
- 1.65
- Payout Ratio
- -0.77
- Dividend Per Share
- 1.2
Operating Metrics
- Operating Cashflow per Share
- 6.79
- Free CashFlow per Share
- 6.19
- Capex to Operating CashFlow
- -0.09
- Capex to Revenue
- -0.03
- Capex to Depreciation
- -0.12
- Return on Invested Capital
- 0.13
- Return on Tangible Assets
- -0.14
- Days Sales Outstanding
- 87.01
- Days Payables Outstanding
- 118.33
- Days of Inventory on Hand
- 99.81
- Receivables Turnover
- 4.19
- Payables Turnover
- 3.08
- Inventory Turnover
- 3.66
- Capex per Share
- -0.6
Balance Sheet
- Cash per Share
- 4,78
- Book Value per Share
- 8,15
- Tangible Book Value per Share
- -18.77
- Shareholders Equity per Share
- 8.15
- Interest Debt per Share
- 28.31
- Debt to Equity
- 3.47
- Debt to Assets
- 0.58
- Net Debt to EBITDA
- 2.64
- Current Ratio
- 1.11
- Tangible Asset Value
- -37,95 Bil.
- Net Current Asset Value
- -53,81 Bil.
- Invested Capital
- 3.47
- Working Capital
- 2,85 Bil.
- Intangibles to Total Assets
- 0.55
- Average Receivables
- 11,10 Bil.
- Average Payables
- 3,40 Bil.
- Average Inventory
- 2823500000
- Debt to Market Cap
- 0.48
Dividends
Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.
| Year | Dividends | Growth |
|---|---|---|
| 2017 | 2 | |
| 2018 | 1 | 0% |
| 2023 | 2 | 100% |
| 2024 | 1 | 0% |
Bristol-Myers Squibb Company Profile
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
- CEO
- Dr. Christopher S. Boerner Ph.
- Employee
- 34.100
- Address
-
430 East 29th Street
New York, 10016
Bristol-Myers Squibb Company Executives & BODs
| # | Name | Age |
|---|---|---|
| 1 |
Dr. Christopher S. Boerner Ph.D. Chief Executive Officer & Chairman |
70 |
| 2 |
Mr. David V. Elkins Executive Vice President & Chief Financial Officer |
70 |
| 3 |
Dr. Joseph J. Eiden Jr. Head of Medical Affairs |
70 |
| 4 |
Ms. Sandra Leung Esq. Executive Vice President & General Counsel |
70 |
| 5 |
Mr. Timothy Power Vice President & Head of Investor Relations |
70 |
| 6 |
Mr. Greg Meyers Executive Vice President and Chief Digital & Technology Officer |
70 |
| 7 |
Ms. Kimberly M. Jablonski Chief Compliance & Ethics Officer |
70 |
| 8 |
Mr. Samit Hirawat M.D. Executive Vice President, Chief Medical Officer & Head of Development |
70 |
| 9 |
Ms. Ahn Amanda Poole Executive Vice President & Chief Human Resources Officer |
70 |
| 10 |
Mr. Adam Lenkowsky Executive Vice President, Chief Commercialization Officer & Head of U.S. Oncology |
70 |